Zapata Gomez Ramon 4
4 · BioNTech SE · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
BioNTech (BNTX) CFO Ramon Zapata Receives Equity Award
What Happened
Ramon Zapata Gomez, BioNTech's CFO, was granted two equity awards on 2026-05-12 totaling 33,982 derivative units: 18,879 units of one award and 15,103 units of another. Both grants were recorded at $0 cash paid (award/grant code A). One award is an option with an exercise price of EUR 89.38; the other consists of performance share units (PSUs) linked to market performance.
Key Details
- Transaction date: 2026-05-12; Form filed: 2026-05-13 (appears timely).
- Grants: 18,879 units (derivative, $0) + 15,103 units (derivative, $0) = 33,982 total units.
- Option exercise price (footnote): EUR 89.38; subject to an adjustment limiting ADS trading price on exercise to no more than 800% of the grant-date exercise price.
- Vesting: Both awards vest annually in equal installments over four years starting on the first anniversary and become exercisable/finally payable four years after grant, subject to service and performance conditions.
- Settlement: Option may be settled in ordinary shares, ADSs and/or cash (supervisory board election). PSUs are economically equivalent to one ordinary share each and may be settled in ordinary shares, an ADS representing one ordinary share, cash, or another form of settlement. PSUs vesting is tied to performance vs. the Nasdaq Biotechnology Index (or successor index).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Filing timeliness: Filed the next day; no late-filing indication in the excerpt.
Context
These are grants/awards (not open-market purchases or sales). Options require exercise (pay exercise price) and PSUs require meeting performance and service conditions before converting into shares/ADSs or cash. Awards like these are common executive compensation and do not, by themselves, indicate immediate buying or selling of stock.
Insider Transaction Report
- Award
Option (right to buy)
[F1][F2][F3]2026-05-12+18,879→ 18,879 totalFrom: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (18,879 underlying) - Award
Performance Share Unit
[F4]2026-05-12+15,103→ 15,103 totalExercise: $0.00From: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (15,103 underlying)
Footnotes (4)
- [F1]The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- [F2]The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- [F3]The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- [F4]Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.